SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD
SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Cardiology (heart failure) Consultation — Duke Kahanamoku
| Patient | Duke Kahanamoku |
|---|
| Date of birth | 1959-08-24 |
|---|
| Identifiers | MRN HR-ML050-SYN; SSN (made up) 000-50-6847 |
|---|
| Document date | 2026-03-30 |
|---|
| Author | Noelani Abernathy-Chen, MD |
|---|
| Custodian | St. Posthumous Health Center |
|---|
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Reason for Referral
Six weeks of breathlessness, ankle swelling and tiredness in a 66-year-old Native Hawaiian man five years after a heart attack, with NT-proBNP 2,450 pg/mL, old anterior Q waves and an enlarged heart on chest X-ray. Please confirm the diagnosis and cause, advise on guideline-directed medical therapy and its order, the ischemic evaluation and device decisions, and how he can return to swimming and surfing safely. [S]
Urgency: Soon; on the day of his two-week visit, after the echocardiogram that morning. [S]
Questions for the consultant:
- Does he have heart failure with reduced ejection fraction, and is the cause ischemic?
- Does he need an ischemic evaluation, and could revascularization help?
- Which guideline-directed medicines should he start, in what order, and how should lisinopril and metoprolol tartrate be changed?
- Should his iron deficiency be treated, and how?
- When should a defibrillator or resynchronization device be considered?
- How and when can he safely return to swimming and surfing?
History of Present Illness
Mr. Kahanamoku, a 66-year-old Native Hawaiian man who is sheriff of Honolulu and a lifelong swimmer and surfer, is seen at the request of Dr. Lindgren-Morrison on the day of his echocardiogram. At his wish, two members of his ʻohana joined the discussion; he made the decisions. He had a heart attack five years ago, treated with medicines. For about eight weeks he has been breathless on slopes and while paddling, with orthopnea and ankle swelling that have eased on two weeks of furosemide. He has no chest pain, palpitations or fainting. He has never smoked or drunk alcohol. [S]
Historical basis. These claims are historical evidence, not findings from a modern examination.
- Duke Kahanamoku was born on August 24, 1890, in Honolulu, at Haleʻākala, the Honolulu home of Princess Bernice Pauahi Bishop; he was named after his father, who had been named Duke for a visit of the Duke of Edinburgh to Hawaiʻi. [D]
- Olympedia gives his full name as Duke Paoa Kahino Makoe Hulikohoa Kahanamoku. [D]
- He won the Olympic 100-meter freestyle in 1912 at Stockholm (with silver in the 4 x 200-meter relay) and again in 1920 at Antwerp (with gold in the relay), and silver in the 100-meter freestyle in 1924 at Paris: three gold and two silver medals. [D]
- He co-founded the Hui Nalu surf club in 1911, introduced surfing to the Atlantic coast of the United States in 1914 and gave a surfing exhibition at Freshwater Beach in Sydney on December 24, 1914, widely regarded as a seminal event for surfing in Australia; he was inducted into the International Swimming Hall of Fame in 1965 and was the first inductee of the International Surfing Hall of Fame in 1966. [D]
- From 1922 he lived in Los Angeles for years and found small roles in many Hollywood films. [D]
- He was elected sheriff of Honolulu for 13 consecutive terms, from 1934 until the post was eliminated in 1960, after which he was named Hawaiʻi's "Ambassador of Aloha"; other sources date his first election to 1932 and his departure to 1961. [D]
- He married Nadine Alexander on August 2, 1940, in Kailua-Kona. [D]
- He never drank alcohol or smoked and trained consistently. [D]
- He had a heart attack in 1952 and suffered several heart attacks in his later years, continuing to swim and sail almost to the end of his life. [D]
- He had no great personal wealth. [D]
- He was the official United States representative at the 1956 Melbourne Olympic Games. [D]
3 later historical claims are omitted because they describe events after the index age. See the teaching note.
Allergies and Intolerances
| Allergy | Reaction | Status | Evidence |
|---|
| No known allergy | | active | S |
Medications
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|
| Aspirin 81 mg delayed-release oral tablet, one tablet daily | One tablet daily | Oral route | 2021-06-21 | active | S |
| Atorvastatin 40 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2021-06-21 to 2026-03-16 | completed | S |
| Atorvastatin 80 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-16 | active | S |
| Metoprolol tartrate 25 mg oral tablet, one tablet twice daily | One tablet twice daily | Oral route | 2021-06-21 to 2026-03-30 | completed | S |
| Lisinopril 10 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2021-06-21 to 2026-03-30 | completed | S |
| Furosemide 40 mg oral tablet, one tablet every morning | One tablet every morning | Oral route | 2026-03-16 to 2026-04-27 | completed | S |
| Sacubitril 24 mg / valsartan 26 mg oral tablet, one tablet twice daily, first dose 36 hours after the last lisinopril | One tablet twice daily | Oral route | 2026-03-30 to 2026-09-28 | completed | S |
| Carvedilol 3.125 mg oral tablet, one tablet twice daily with food, starting the evening after the last metoprolol tartrate | One tablet twice daily with food | Oral route | 2026-03-30 to 2026-04-13 | completed | S |
| Empagliflozin 10 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating or drinking | One tablet daily, with sick-day rules | Oral route | 2026-03-30 | active | S |
| Ferric carboxymaltose 750 mg (15 mL vial, 50 mg/mL) by intravenous infusion, two doses two weeks apart | Two infusions two weeks apart | Intravenous route | 2026-03-30 to 2026-04-13 | completed | S |
Problems
| Problem | Clinical status | Verification | Code | Provenance |
| Breathlessness on exertion for six weeks (paddling out, walking uphill, finishing his morning swim), with ankle swelling by evening and tiredness, five years after a heart attack; cause to be determined | resolved | confirmed |
R06.09 | S — Synthetic presenting problem, resolved at the second visit when the echocardiogram and cardiology established heart failure with reduced ejection fraction. |
| Coronary artery disease with an old anterior myocardial infarction five years ago, treated with medicines; synthetic modern episode linked to the documented heart attack of 1952 | active | confirmed |
I25.2 | S — Synthetic modern diagnosis; the 1952 heart attack remains D in the history. |
| Heart failure with reduced ejection fraction from ischemic cardiomyopathy (ejection fraction 30% with a thinned, akinetic anterior wall and apex), NYHA class III at diagnosis | active | confirmed |
I50.22 | S — Synthetic modern diagnosis made at the second visit; no claim that he had heart failure in his lifetime. |
| Iron deficiency without anemia (ferritin 62 ng/mL, transferrin saturation 16%) | active | confirmed |
E61.1 | S — Synthetic finding at the heart failure workup. |
Physical Exam
Vital signs recorded on 2026-03-30; see the referring visit's Vital Signs section. [S]
| System | Finding |
|---|
| General | Comfortable at rest; blood pressure 134/82, pulse 86; weight 95.0 kg |
| Neck | Jugular venous pressure 3 cm above the sternal angle |
| Cardiovascular | Regular rhythm; displaced apex; soft S3; apical systolic murmur of functional mitral regurgitation |
| Respiratory | Fine crackles at both bases only |
| Extremities | Trace ankle edema |
Results
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
| 2026-03-30 | Sodium [Moles/volume] in Serum or Plasma | 137 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-03-30 | Potassium [Moles/volume] in Serum or Plasma | 3.9 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-03-30 | Creatinine [Mass/volume] in Serum or Plasma | 1.08 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-03-30 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 76 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-03-30 | Glucose [Mass/volume] in Serum or Plasma | 98 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-03-30 | Magnesium [Mass/volume] in Serum or Plasma | 1.9 | mg/dL | 1.6-2.6 mg/dL | Normal | S |
| 2026-03-30 | Left ventricular Ejection fraction | 30 | % | 50-70% | Low | S |
Assessment
- Diagnosis and cause (I50.22). Heart failure with reduced ejection fraction, stage C, NYHA class III, from ischemic cardiomyopathy: an ejection fraction of 30% with a thinned, akinetic anterior wall and apex in the territory of the old anterior infarction, and Q waves to match. The mitral regurgitation is functional, from the dilated ventricle. TSH and blood count exclude thyroid disease and anemia as contributors; he does not drink alcohol. [S]
- Ischemic evaluation (I25.2). Invasive coronary angiography is reasonable in new HFrEF with a likely coronary cause, to define the anatomy and look for disease that revascularization could help, especially in vessels other than the infarct artery. A thinned, akinetic wall of 5 mm or less is unlikely to recover even if its artery is opened. [S]
- Guideline-directed medical therapy (I50.22). Start all four classes within weeks rather than months. Stop lisinopril and begin sacubitril-valsartan 24/26 mg twice daily at least 36 hours after the last lisinopril dose, to avoid angioedema. Replace metoprolol tartrate, which is not one of the beta-blockers proven in heart failure, with carvedilol 3.125 mg twice daily. Start empagliflozin 10 mg now. Add spironolactone 12.5 mg at the next visit if potassium is below 5.0 mmol/L and eGFR above 30. Then raise one medicine every two weeks toward target doses (sacubitril-valsartan 97/103 mg and carvedilol 25 mg twice daily) as blood pressure, heart rate, potassium and kidney function allow, with a metabolic panel one to two weeks after each change. Keep furosemide at the lowest dose that keeps him dry. Teach sick-day rules. [S]
- Iron deficiency (E61.1). Ferritin below 100 ng/mL is iron deficiency in heart failure even without anemia. Intravenous iron improves symptoms, exercise capacity and quality of life; oral iron does not. Give ferric carboxymaltose 750 mg today and again in two weeks, and check iron studies at about six months. [S]
- Defibrillator and resynchronization. Not now. Repeat the echocardiogram after at least 90 days of optimized therapy; a primary-prevention ICD is indicated if the ejection fraction is still 35% or below with NYHA class II to III and a good expected survival. His QRS of 104 ms does not meet criteria for resynchronization. [S]
- Exercise and the ocean. Exercise training is safe and helps in stable HFrEF. Cardiac rehabilitation for heart failure is covered once he has had six weeks of stable therapy and no procedure in the previous six weeks. Until then, walking. After rehabilitation, swimming is reasonable in calm water with a companion; breath-hold diving and big surf should wait until he is clearly stable, because a sudden loss of consciousness in the water is the main danger. Drink water through the morning on the diuretic and empagliflozin. [S]
Data reviewed: Dr. Lindgren-Morrison's intake note. ECG: sinus rhythm, Q waves in V1 to V4, QRS 104 ms, no left bundle branch block. Chest X-ray: enlarged heart, upper-lobe venous diversion and small effusions. NT-proBNP 2,450 pg/mL. Echocardiogram this morning: ejection fraction 30% by biplane method, thinned and akinetic anterior wall and apex, left ventricular end-diastolic diameter 62 mm, no thrombus, moderate functional mitral regurgitation, normal right ventricle, estimated pulmonary artery systolic pressure 42 mmHg. Metabolic panel today: potassium 3.9 mmol/L, creatinine 1.08 mg/dL (eGFR 76), magnesium 1.9 mg/dL. Ferritin 62 ng/mL, transferrin saturation 16%, hemoglobin 13.4 g/dL; TSH 2.1; LDL 92 mg/dL on atorvastatin 40 mg. [S]
Plan of Treatment
- Stop lisinopril; start sacubitril-valsartan 24/26 mg twice daily 36 hours after the last dose. [S]
- Change metoprolol tartrate to carvedilol 3.125 mg twice daily. [S]
- Start empagliflozin 10 mg daily with sick-day rules. [S]
- Add spironolactone 12.5 mg daily at the next visit if potassium is below 5.0 mmol/L and eGFR above 30. [S]
- Raise one medicine every two weeks toward target doses, with a metabolic panel one to two weeks after each change. [S]
- Continue furosemide at the lowest dose that keeps him euvolemic. [S]
- Ferric carboxymaltose 750 mg intravenously today and in two weeks; iron studies at about six months. [S]
- Invasive coronary angiography within two weeks. [S]
- Repeat echocardiogram after at least 90 days of optimized therapy to decide on a primary-prevention ICD. [S]
- Cardiac rehabilitation for heart failure when eligible, then a graded return to the ocean. [S]
- Pneumococcal vaccine now; influenza, COVID-19 and RSV vaccines in the autumn. [S]
- Discussed with Dr. Lindgren-Morrison, who saw him the same day. The diagnosis, each medicine and the angiography were explained plainly to Mr. Kahanamoku and, at his wish, to members of his ʻohana; he agreed to the plan. [S]
- Follow-up: Dr. Lindgren-Morrison continues his care, with the heart failure nurse for titration. Cardiology will review the angiogram and the repeat echocardiogram, and will see him sooner for worsening symptoms, fainting or palpitations. [S]